latest update:
[TrialBase DB]

trial summary · NCT07635056

Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma

Trial record from the TrialBase DB dataset, status RECRUITING, condition Neuroblastoma, sponsored by Children's Hospital Medical Center, Cincinnati. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07635056phase PHASE2enrollment 20start 2026-12

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The goal of this study is to demonstrate that cytokine-induced memory-like natural killer cells (CIML-NK cells) can be generated from donor cells and infused safely into patients with relapsed or refractory neuroblastoma during dinutuximab-based therapy.

Source record: https://clinicaltrials.gov/study/NCT07635056

Facts

registry idNCT07635056
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionNeuroblastoma
sponsorChildren's Hospital Medical Center, Cincinnati
sponsor classOTHER
enrollment20
start date2026-12
primary completion2031-06
completion2031-06
results postednot reported

Conditions

  • Neuroblastoma

Interventions

  • CIML-NK Cells

Countries

  • United States

Intervention types: BIOLOGICAL

Work with this record